Updated:
Elevage Medical Technologies
Sidney Knafel founded Elevage Medical Technologies in 2022 as the single-family office for his post-exit wealth.
Elevage Medical Technologies
Sidney Knafel founded Elevage Medical Technologies in 2022 as the single-family office for his post-exit wealth. The capital traces back to Knafel's earlier career building and ultimately selling a large contract manufacturer serving the medical device industry, a business now operating as part of a global strategic acquirer. The office reflects that operating DNA: it invests not just capital but also engineering, manufacturing, and regulatory resources into the companies it backs. The firm targets early-stage to growth-stage medical device companies across the United States and Western Europe. Its strategy combines direct equity investments with active operational support — drawing on Knafel's manufacturing expertise to help portfolio companies navigate the FDA clearance process, scale production, and build out their supply chains. Known asset classes include direct venture equity and convertible notes, and the firm has indicated it will write initial checks in the $2 million to $10 million range. Confirmed focus areas include cardiovascular devices, surgical robotics, and neuromodulation technologies. Elevage operates from Tampa, Florida, with a lean team led by Knafel and Managing Director Dr. Evan Melrose, a physician-turned-investor. The firm does not operate a philanthropic foundation but has disclosed that its capital is fully committed to for-profit healthcare innovation. In 2022, Elevage publicly announced its $100 million initial deployment target with a multi-year investment horizon (per the firm, 2022). The structure allows for patient capital deployment without the fixed-life constraints of traditional venture funds. Structurally, what separates Elevage from a typical venture firm is its embedded operating capability. Knafel maintains a controlling interest in a separate contract manufacturing entity that can serve as a production partner for portfolio companies — an architecture that offers founders a clear path from prototype to scaled commercial manufacturing without the sourcing risks that typically slow down hardware-focused healthtech startups.
General information
Firm type
Single Family Office
Year founded
2022
AUM
$100M–$250M (Altss estimate)
Location
Region
North America
Country
United States
City
Tampa
Corporate office
Tampa, FL, United States
Principals
Sidney R. Knafel
Founder and Managing Partner
Evan Melrose, MD
Managing Director
Sector focus
Frequently asked questions
Who runs investment decisions at Elevage Medical Technologies?
Founder and Managing Partner Sidney Knafel leads the investment committee alongside Managing Director Dr. Evan Melrose. Knafel brings over 40 years of operating experience in medical device manufacturing to the decision process. The firm's small team structure means investment decisions rely heavily on the principals' direct sector knowledge and manufacturing insights.
How is Elevage Medical Technologies structured relative to a traditional venture capital firm?
Elevage operates as a single-family office deploying Knafel family capital, not third-party LP commitments. This structure frees it from traditional fund lifecycle pressures and allows for longer holding periods. It also integrates Knafel's separate contract manufacturing capabilities, giving portfolio companies a pathway from prototype to commercial-scale production that pure-play VCs cannot offer.
Does Elevage participate in fund commitments or only direct deals?
Publicly available information indicates Elevage focuses on direct investments into operating companies rather than fund commitments. The firm's model relies on active operational engagement, which is incompatible with passive LP positions in third-party funds.
What investment stages does Elevage Medical Technologies typically target?
Elevage targets early-stage to growth-stage companies, with announced initial check sizes in the $2 million to $10 million range. The firm has publicly stated a focus on companies that have moved beyond pure concept stage and are preparing for or have recently achieved FDA regulatory milestones.
Where does the underlying wealth come from?
The family capital deployed by Elevage originates from Sidney Knafel's sale of a large medical device contract manufacturing business that he founded and led. The acquirer was a strategic buyer in the medical device space, and Knafel retained significant post-transaction capital that now funds Elevage's investment activities.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: